申请人:Glaxo Group Limited
公开号:US04315006A1
公开(公告)日:1982-02-09
Compounds are disclosed of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom or C.sub.1-4 alkyl or C.sub.2-4 alkenyl group, or the group COANH.sub.2, CSANH.sub.2, or COANHCOCH.sub.2 NH.sub.2 in which A is methylene optionally substituted by a C.sub.1-3 alkyl group; and R.sub.2 represents a hydrogen atom or a C.sub.1-4 alkyl group; or NR.sub.1 R.sub.2 forms a piperidino, piperazino or N-methylpiperazino group; R.sub.3 represents a C.sub.1-4 alkyl group or a benzyl group; R.sub.4 represents a hydrogen or halogen atom; and R.sub.5 represents a hydrogen atom or a C.sub.1-4 alkyl or C.sub.1-4 alkoxy group, with the proviso that one of R.sub.4 and R.sub.5 is a hydrogen atom and physiologically acceptable salts and bioprecursors thereof. The compounds exert effects on the central nervous system and, in particular exhibit anxiolytic and anti-convulsant activity. The compounds may be formulated with pharmaceutically acceptable carriers or diluents for administration in conventional manner.
揭示了一般式为##STR1##的化合物,其中R.sub.1代表氢原子或C.sub.1-4烷基或C.sub.2-4烯基基团,或基团COANH.sub.2,CSANH.sub.2,或COANHCOCH.sub.2 NH.sub.2,其中A是亚甲基,可选择地被C.sub.1-3烷基基团取代;R.sub.2代表氢原子或C.sub.1-4烷基基团;或NR.sub.1 R.sub.2形成哌啶基、哌嗪基或N-甲基哌嗪基;R.sub.3代表C.sub.1-4烷基或苄基;R.sub.4代表氢原子或卤素原子;R.sub.5代表氢原子或C.sub.1-4烷基或C.sub.1-4烷氧基团,但R.sub.4和R.sub.5中的一个为氢原子,其生理上可接受的盐和生物前体。这些化合物对中枢神经系统产生影响,特别表现出抗焦虑和抗惊厥活性。这些化合物可以与药用可接受的载体或稀释剂配制,以常规方式进行给药。